Clinical trials: Locally Advanced Gastric Adenocarcinoma
Non-small Cell Lung Cancer, Gastric Cancer
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05867121
- Testing
- RO7496353, Atezolizumab, Capecitabine
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Gastric/Gastroesophageal Junction Adenocarcinoma
Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma
This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.
- Trial name
- NCT06764251
- Testing
- Tislelizumab + SOX
- Volunteers
- 20 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Stomach Neoplasms, Neoadjuvant Therapy
A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma
This prospective, randomized phase II study is designed to evaluate weather neoadjuvant chemoradiotherapy is superior to neoadjuvant chemotherapy with both followed by surgery and postoperative chemotherapy for locally advanced…
- Conditions
- Stomach Neoplasms, Neoadjuvant Therapy, Chemoradiotherapy, Chemotherapy
- Trial name
- NCT02301481
- Testing
- SIB-IMRT, S-1, Surgery
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Chinese Academy of Medical Sciences
Locally Advanced Unresectable Gastric Adenocarcinoma
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
The efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.
- Trial name
- NCT05974059
- Testing
- Oxaliplatin, Capecitabine, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
Gastric cancer is one of the most common and deadly cancers globally, characterized by a poor prognosis. Approximately 70% of patients are diagnosed at an advanced stage, and the 5-year survival rate is only around 10%.
- Trial name
- NCT06985602
- Testing
- Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Stomach Neoplasms, Esophageal Neoplasms
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Trial name
- NCT00813072
- Testing
- PEP02, irinotecan, docetaxel
- Where
- 22 sites in Bosnia and Herzegovina, Croatia and 4 more
- Volunteers
- 135 people
- Sponsor
- PharmaEngine
Gastric Cancer
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer
This is a prospective pilot study to evaluate the safety and feasibility of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and gastroesophageal junction.
- Trial name
- NCT05396326
- Testing
- Oxaliplatin, Teysuno, Transarterial arterial chemoinfusion and embolism (TACiE)
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy
Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric
This is a single-arm, exploratory clinical study to evaluate the efficacy and safety of Preoperative short course radiotherapy with Envafolimab, Endostatin and SOX regimen in resectable locally advanced gastric/gastroesophageal…
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy
- Trial name
- NCT05387681
- Testing
- Envafolimab
- Volunteers
- 35 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
A randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for locally advanced…
- Trial name
- NCT05008783
- Testing
- AK104
- Where
- 7 sites in China
- Volunteers
- 610 people
- Sponsor
- Akeso
Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma
This study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal…
- Trial name
- POSIT (NCT07674342)
- Testing
- Short-course Radiotherapy, Neoadjuvant Serplulimab and SOX Chemotherapy
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Tongji Hospital
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Stomach and Gastro-Esophageal Junction (GEJ) Cancer
Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer
The investigators propose to study the efficacy and safety of nab-Paclitaxel in a Phase II trial of patients with locally advanced or metastatic adenocarcinomas of the stomach and gastro-esophageal junction
- Trial name
- NCT02251951
- Testing
- nab-Paclitaxel
- Where
- 6 sites in Greece
- Volunteers
- 39 people
- Sponsor
- Hellenic Oncology Research Group
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric/GEJ Cancer
This prospective observational study will enroll 120 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who are scheduled to receive neoadjuvant immunotherapy followed by radical surgery.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Sleep, Pathological Response
- Trial name
- NCT07662005
- Testing
- Not applicable- observational study
- Volunteers
- 120 people
- Sponsor
- West China Second University Hospital
Gastroesophageal Junction Adenocarcinoma
Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma
Preoperative chemoradiotherapy(CRT) had been introduced in the comprehensive treatment of gastroesophageal junction and upper gastric cancers in the decade.According to some researches,CRT had shown its good curative effects in…
- Trial name
- NCT02193594
- Testing
- Preoperative concurrent chemoradiotherapy, Radical D2 total gastrectomy, Adjuvant chemotherapy
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Peking University
CLDN18.2 Positive, Primary Gastric Adenocarcinoma
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a prospective, randomized, open, multicenter phase II clinical trial. It plans to enroll 70 participants with locally advanced gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC) who are assessed as…
- Conditions
- CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07483567
- Testing
- IBI343,sintilimab,oxaliplatin,S-1, sintilimab,oxaliplatin,S-1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Gastric or Gastroesophageal Junction Adenocarcinoma
Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
This is a retrospective, multicenter, non-interventional study for the evaluation of real-world efficacy and safety of ramucirumab plus paclitaxel in gastric or gastroesophageal junction adenocarcinoma as part of the…
- Trial name
- NCT04192734
- Where
- 57 sites in South Korea
- Volunteers
- 1,063 people
- Sponsor
- Hallym University Medical Center
Gastric Cancer
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
RATIONALE: Drugs used in chemotherapy, such as docetaxel and epirubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075465
- Testing
- docetaxel, epirubicin hydrochloride
- Where
- 23 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and…
- Trial name
- NCT01585987
- Testing
- Ipilimumab, Best Supportive care (BSC)
- Where
- 36 sites in United States, France and 10 more
- Volunteers
- 143 people
- Sponsor
- Bristol-Myers Squibb
Gastric Neoplasms, Gastroesophageal Adenocarcinoma
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
- Conditions
- Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- HERIZON-GEA-01 (NCT05152147)
- Testing
- Zanidatamab, Tislelizumab, Trastuzumab
- Where
- 227 sites in Argentina, Australia and 31 more
- Volunteers
- 920 people
- Sponsor
- Jazz Pharmaceuticals
Gastric Cancer, Hepatocellular Carcinoma
Personalized DC Vaccine for Postoperative Cancer
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and…
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
- Trial name
- NCT04147078
- Testing
- DC vaccine subcutaneous administration
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University